Datasheet for ABIN5668217

Recombinant anti-CD22 (Epratuzumab Biosimilar) antibody

| 3 | Images |

Overview

Quantity:	200 µg
Target:	CD22 (Epratuzumab Biosimilar)
Reactivity:	Human, Cynomolgus, Rhesus Monkey
Host:	Rabbit
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
Application:	Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)

Product Details

|	
Immunogen:	This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
Clone:	HL22
Isotype:	IgG kappa
Specificity:	This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
Characteristics:	OriginalSpeciesName: Human OriginalFormat: IgG1
Purification:	Purified antibody.

Product Details

Purity:	> 98 % as determined by SDS-PAGE
Endotoxin Level:	Endotoxin is < 1.0 EU/mg as determined by the LAL method

Target Details

Target:	CD22 (Epratuzumab Biosimilar)
Abstract:	CD22 (Epratuzumab Biosimilar) Products
Target Type:	Biosimilar
Background:	Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
UniProt:	P20273

Application Details

Application Notes:	Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
Comment:	This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Restrictions:	For Research Use only

Handling

|	
Buffer:	PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Images

Flow Cytometry

Image 1. Flow-cytometry using anti-CD22 antibody Epratuzumab Human lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Eptratuzumab (panel B) at a concentration of 1 μg/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody (ab150073) and cells analysed on a FACSCanto flow-cytometer.

Flow Cytometry

Image 2. Flow-cytometry using anti-CD22 antibody Epratuzumab Rhesus monkey lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Epratuzumab (panel B) at a concentration of 1 μg/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody (ab150073) and cells analysed on a FACSCanto flow-cytometer.

Flow Cytometry

Image 3. Flow-cytometry using anti-CD22 antibody Epratuzumab Cynomolgus monkey lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Epratuzumab (panel B) at a concentration of 1 μg/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody (ab150073) and cells analysed on a FACSCanto flow-cytometer.